Platelet function measurement in elective percutaneous coronary intervention patients: exploring the concept of a P2Y₁₂ inhibitor therapeutic window.
نویسندگان
چکیده
When clopidogrel was first clinically used, the relation between the pharmacodynamic effect and thrombotic event occurrence was unknown. Moreover, when the new P2Y12 inhibitors were developed, the desired level of on-treatment platelet reactivity to adenosine diphosphate to avoid ischemic event occurrence was highly debated and some recommended that near-100% inhibition should be the target. Concern surrounding the clinical implications of aggregometrydefined poor platelet inhibition in clopidogrel-treated elective percutaneous coronary intervention (PCI) patients arose over 1 decade ago (1). In that study, approximately 30% had a 10% decrease in aggregation at 24 h after a 300-mg load; these patients were defined as resistant. It was suggested that, “further study is necessary to investigate the mechanisms of these findings and how they correlate with the occurrence of ischemic events” (1).
منابع مشابه
اثر PercutaneousCoronary Intervention Elective بر بهبودی نارسایی ایسکمیک میترال
Introdution: Ischemic mitral regurgitation (IMR) remains one of the most complex and unresolved aspects of ischemic heart disease that the impact of percutaneous coronary intervention (PCI) on improvement of intensity of ischemic mitral regurgitation is not well clarified. Patients with coronary artery diseases and ischemic mitral regurgitation have a worse prognosis than the patients with coro...
متن کاملTreatment Inhibitors by Transfusion of Platelets in an Urgent or Delayed Timing After Acute Coronary Syndrome or Percutaneous Coronary Intervention Presentation-Acute Coronary Syndrome
The addition of P2Y12 receptor inhibiting drugs to aspirin therapy has resulted in improved clinical outcome secondary to reduced recurrent ischemic events in patients with acute coronary syndromes (ACS) or after percutaneous coronary intervention (PCI). The ischemic benefit is offset by significant morbidity and mortality associated with major bleeding complications in the both coronary artery...
متن کاملCytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
BACKGROUND Among patients treated with clopidogrel, carriers of the cytochrome P450 (CYP) 2C19 loss-of-function allele have shown increased platelet reactivity and higher rates of ischemic events. Although adjunctive cilostazol to dual antiplatelet therapy (or "triple antiplatelet therapy") intensifies platelet inhibition, it remains unknown whether triple antiplatelet therapy after percutaneou...
متن کاملPlatelet-To-Lymphocyte Ratio as a Predictor of No-Reflow after Primary Percutaneous Coronary Intervention in Patients with ST Elevation Myocardial Infarction: A Systematic Review and Meta-Analysis
Introduction: No-reflow increases the complications and mortality rate of primary percutaneous coronary intervention (PCI). Therefore, it is important to identify patients at a higher risk of developing no-reflow. This study aimed to systematically review the prognostic value of the platelet-to-lymphocyte ratio (PLR) to predict no-reflow. Materials and Methods:</s...
متن کاملOn aspirin treatment but not baseline thromboxane B2 levels predict adverse outcomes in patients with acute coronary syndromes.
R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, van Werkum JW, Paganelli F, Price MJ, Waksman R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56: 919– 33. 8 Freynhofer MK, Bruno V, Willheim M, Hübl W, Wojta J, Huber K. Vasodi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- JACC. Cardiovascular interventions
دوره 5 3 شماره
صفحات -
تاریخ انتشار 2012